VolitionRx (NYSE:VNRX) Now Covered by StockNews.com

StockNews.com started coverage on shares of VolitionRx (NYSE:VNRX) in a report published on Sunday morning. The firm issued a sell rating on the stock.

A number of other equities analysts have also commented on the company. D. Boral Capital reissued a “buy” rating and issued a $5.00 price objective on shares of VolitionRx in a research note on Monday, March 31st. HC Wainwright began coverage on shares of VolitionRx in a report on Tuesday, April 8th. They set a “buy” rating and a $2.50 target price for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. According to MarketBeat, VolitionRx has an average rating of “Hold” and an average price target of $3.33.

VolitionRx Trading Up 0.8 %

NYSE VNRX opened at $0.49 on Friday. The firm has a market cap of $49.16 million, a price-to-earnings ratio of -1.36 and a beta of 1.15. VolitionRx has a 1-year low of $0.42 and a 1-year high of $1.02. The company has a 50 day moving average of $0.56 and a 200-day moving average of $0.62.

Insiders Place Their Bets

In other news, CEO Cameron John Reynolds bought 181,818 shares of the stock in a transaction on Wednesday, March 26th. The stock was purchased at an average price of $0.55 per share, for a total transaction of $99,999.90. Following the acquisition, the chief executive officer now owns 2,299,222 shares in the company, valued at approximately $1,264,572.10. This trade represents a 8.59 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 12.80% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of VNRX. Two Sigma Securities LLC acquired a new position in VolitionRx during the fourth quarter valued at approximately $29,000. Millennium Management LLC acquired a new position in shares of VolitionRx during the 4th quarter worth approximately $36,000. Northern Trust Corp increased its position in shares of VolitionRx by 32.0% in the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock worth $71,000 after purchasing an additional 28,579 shares during the period. Geode Capital Management LLC increased its stake in VolitionRx by 15.1% in the third quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock valued at $439,000 after acquiring an additional 95,900 shares during the last quarter. Finally, Lagoda Investment Management L.P. raised its stake in VolitionRx by 24.3% during the fourth quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock worth $4,546,000 after acquiring an additional 1,481,000 shares in the last quarter. 8.09% of the stock is currently owned by institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.